Abstract
Regions of hypoxia are a common feature of solid tumours. When tumour cells are exposed to hypoxic stress, transcription of a battery of genes is initiated. The angiogenic factor adrenomedullin (ADM) is a hypoxia regulated gene. ADM is thought to act through the G protein-coupled receptor calcitonin receptor-like receptor (CRLR), with specificity being conferred by the receptor associated modifying protein 2 (RAMP2). Here we report for the first time that ADM treated or stably transfected Ishikawa cells overexpressing ADM show increased resistance to hypoxia induced apoptosis. These cells also show an upregulation of the oncoprotein Bcl-2, which is protective against hypoxic cell death when transiently transfected into Ishikawa cells. Since Ishikawa cells express the putative ADM-receptor CRLR–RAMP2 the production and secretion of ADM with the consecutive upregulation of Bcl-2 could establish an autocrine/paracrine mechanism rescuing malignant cells from hypoxic cell death. These results, taken together with our previous findings that ADM is an angiogenic factor which is upregulated by the nonsteroidal antiestrogen tamoxifen (TAM) in endometrial cells, implicate this peptide as a promoter of tumour growth and a possible target for anticancer strategies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- ADM:
-
adrenomedullin
- CRLR:
-
calcitonin receptor-like receptor
- Epo:
-
erythropoietin
- HIF-1:
-
hypoxia-inducible transcription factor-1
- IGFBP-1:
-
insulin-like growth factor binding protein l
- PD-ECFG/TP:
-
platelet-derived endothelial cell growth factor/thymidine phosphorylase
- RAMP2:
-
receptor associated modifying protein
- TAM:
-
tamoxifen
- VEGF:
-
vascular endothelial growth factor.
References
Adams JM, Cory S . 1998 Science 281: 1322–1326
Alarcon RM, Rupnow BA, Graeber TG, Knox SJ, Giaccia AJ . 1996 Cancer Res. 56: 4315–4319
Barakat R . 1996 Clin. Obstet. Gynecol. 39: 629–640
Bergman L, Beelen M, Gallee M, Hollema H, Benraadt J, van Leeuwen F . 2000 Lancet 356: 881–887
Blancher C, Harris AL . 1998 Cancer Metas. Rev. 17: 187–194
Caron KM, Smithies O . 2001 Proc. Natl. Acad. Sci. USA. 98: 615–619
Carthew P, Edwards R, Nolan B, Martin E, Heydon R, White, Tucker M . 2000 Carcinogenesis 21: 793–797
Cormier-Regard S, Nguyen SV, Claycomb WC . 1998 J. Biol. Chem. 273: 17787–17792
Cory S, Vaux DL, Strasser A, Harris AW, Adams JM . 1999 Cancer Res. 59: 1685s–1692s
Cuzick J . 2000 Eur. J. Cancer 36: 1298–1302
Elkas J, Armstrong A, Pohl J, Cuttitta F, Martinez A, Gray K . 2000 Obstet. Gynecol. 95: 697–703
Evans SM, Koch CJ, Laughlin KM, Jenkins WT, Van Winkle T, Wilson DF . 1997 Cancer Res. 57: 5155–5161
Furman E, Rushkin E, Margalit R, Bendel P, Degani H . 1992 J. Steroid Biochem. Mol. Biol. 43: 189–195
Garayoa M, Martinez A, Lee S, Pio R, An WG, Neckers L, Trepel J, Montuenga LM, Ryan H, Johnson R, Gassmann M, Cuttitta F . 2000 Mol. Endocrinol. 14: 848–862
Gleadle JM, Ebert BL, Firth JD, Ratcliffe PJ . 1995 Am. J. Physiol. 268: C1362–C1368
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ . 1996 Nature 379: 88–91
Hague S, Zhang L, Oehler MK, Manek S, MacKenzie IZ, Bicknell R, Rees MC . 2000 Clin. Cancer Res. 6: 2808–2814
Hinson JP, Kapas S, Smith DM . 2000 Endocr. Rev. 21: 138–167
Hockel M, Schlenger K, Hockel S, Vaupel P . 1999 Cancer Res. 59: 4525–4528
Hofbauer KH, Jensen BL, Kurtz A, Sandner P . 2000 Am. J. Physiol. Regul. Integr. Comp. Physiol. 278: R513–R519
Ishimitsu T, Kojima M, Kangawa K, Hino J, Matsuoka H, Kitamura K, Eto T, Matsuo H . 1994 Biochem. Biophys. Res. Commun. 203: 631–539
Jager R, Herzer U, Schenkel J, Weiher H . 1997 Oncogene 15: 1787–1795
Kamitani S, Asakawa M, Shimekake Y, Kuwasako K, Nakahara K, Sakata T . 1999 FEBS Lett. 448: 111–114
Kato H, Shichiri M, Marumo F, Hirata Y . 1997 Endocrinology 138: 2615–2620
Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T . 1993 Biochem. Biophys. Res. Commun. 192: 553–560
McGill G . 1997 Front Biosci. 2: d353–d579
McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM . 1998 Nature 393: 333–339
Miller MJ, Martinez A, Unsworth EJ, Thiele CJ, Moody TW, Elsasser T, Cuttitta F . 1996 J. Biol. Chem 271: 23345–23351
Naik P, Karrim J, Hanahan D . 1996 Genes Dev. 10: 2105
Nakayama M, Takahashi K, Murakami O, Shirato K, Shibahara S . 1998 Biochem. Biophys. Res. Commun. 243: 514–517
Nguyen SV, Claycomb WC . 1999 Biochem. Biophys. Res. Commun. 265: 382–386
Nör JE, Christensen J, Mooney DJ, Polverini PJ . 1999 Am. J. Pathol. 154: 375–384
Ongkeko W, Ferguson DJ, Harris AL, Norbury C . 1995 J. Cell. Sci. 108: 2897–2904
Parameswaran N, Nambi P, Brooks DP, Spielman WS . 1999 Eur. J. Pharmacol. 372: 85–95
Pellegrini M, Strasser A . 1999 J. Clin. Immunol. 19: 365–377
Petersen N, Larsen L, Nissen H, Jensen L, Jensen A, Petersen P, Horder M, Gregersen N, Kristiansen K . 1995 Clin. Chem. 41: 1605–1613
Ricca A, Biroccio A . 2000 Int. J. Cancer 86: 188–196
Sakuragi N, Ohkouchi T, Hareyama H . 1998 Int. J. Cancer 79: 153–158
Shichiri M, Kato H, Doi M, Marumo F, Hirata Y . 1999 Mol. Endocrinol. 13: 1353–1363
Shimizu S, Eguchi Y, Kamiike W, Itoh Y, Hasegawa J, Yamabe K, Otsuki Y, Matsuda H, Tsujimoto Y . 1996 Cancer Res. 56: 2161–2166
Shimizu S, Eguchi Y, Kosaka H, Kamiike W, Matsuda H, Tsujimoto Y . 1995 Nature 374: 811–813
Thomlinson R, Gray L . 1995 Br. J. Cancer 9: 539–549
Vaupel P . 1993 Drug Resistance in Oncology. Teicher B (ed) Marcel Dekker: New York pp. 53–85
Wimalawnsa SJ . 1997 Crit. Rev. Neurobiol. 11: 167–239
Yamabe K. Shimizu S, Kamiike W, Waguri S, Eguchi Y, Hasegawa J, Okuno S, Yoshioka Y, Ito T, Sawa Y, Uchiyama Y, Tsujimoto Y, Matsuda H . 1998 Biochem. Biophys. Res. Commun. 243: 217–223
Yang J . 1997 Science 275: 1129–1132
Zhao Y, Hague S, Manek S, Zhang L, Bicknell R, Rees MC . 1998 Oncogene 16: 409–415
Acknowledgements
We thank Drs S Tafuro and M Goern (Institute of Molecular Medicine, Oxford) for their technical expertise and help in FACScan experiments and Helen Turley (Department of Cellular Science, University of Oxford) for help with the immunohistochemistry. Dr MK Oehler was supported by a postdoctoral fellowship from the Deutsche Forschungsgemeinschaft (Oe-230.1-1).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oehler, M., Norbury, C., Hague, S. et al. Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth. Oncogene 20, 2937–2945 (2001). https://doi.org/10.1038/sj.onc.1204422
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204422
Keywords
This article is cited by
-
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)
Journal of Translational Medicine (2022)
-
Adrenomedullin, a Novel Target for Neurodegenerative Diseases
Molecular Neurobiology (2018)
-
Adrenomedullin promotes angiogenesis in epithelial ovarian cancer through upregulating hypoxia-inducible factor-1α and vascular endothelial growth factor
Scientific Reports (2017)
-
The Role of the Calcitonin Peptide Family in Prostate Cancer and Bone Metastasis
Current Molecular Biology Reports (2017)
-
Adrenomedullin and tumour microenvironment
Journal of Translational Medicine (2014)